1zuc: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:1zuc.gif|left|200px]]
{{Seed}}
[[Image:1zuc.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1zuc|  PDB=1zuc  |  SCENE=  }}  
{{STRUCTURE_1zuc|  PDB=1zuc  |  SCENE=  }}  


'''Progesterone receptor ligand binding domain in complex with the nonsteroidal agonist tanaproget'''
===Progesterone receptor ligand binding domain in complex with the nonsteroidal agonist tanaproget===




==Overview==
<!--  
Progesterone receptor (PR) agonists have several important applications in women's health, such as in oral contraception and post-menopausal hormone therapy. Currently, all PR agonists used clinically are steroids. Because of their interactions with other steroid receptors, steroid-metabolizing enzymes, or other steroid-signaling pathways, these drugs can pose significant side effects in some women. Efforts to discover novel nonsteroidal PR agonists with improved biological properties led to the discovery of tanaproget (TNPR). TNPR binds to the PR from various species with a higher relative affinity than reference steroidal progestins. In T47D cells, TNPR induces alkaline phosphatase activity with an EC(50) value of 0.1 nm, comparable with potent steroidal progestins such as medroxyprogesterone acetate (MPA) and trimegestone (TMG), albeit with a reduced efficacy ( approximately 60%). In a mammalian two-hybrid assay to measure PR agonist-induced interaction between steroid receptor co-activator-1 and PR, TNPR showed similar potency (EC(50) value of 0.02 nm) and efficacy to MPA and TMG. Importantly, in key animal models such as the rat ovulation inhibition assay, TNPR demonstrates full efficacy and an enhanced progestational potency (30-fold) when compared with MPA and TMG. Furthermore, TNPR has relatively weak interactions with other steroid receptors and binding proteins and little effect on cytochrome P450 metabolic pathways. Finally, the three-dimensional crystal structure of the PR ligand binding domain with TNPR has been delineated to demonstrate how this nonsteroidal ligand achieves its high binding affinity. Therefore, TNPR is a structurally novel and very selective PR agonist with an improved preclinical pharmacological profile.
The line below this paragraph, {{ABSTRACT_PUBMED_15937332}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 15937332 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_15937332}}


==About this Structure==
==About this Structure==
Line 43: Line 47:
[[Category: Progesterone receptor]]
[[Category: Progesterone receptor]]
[[Category: Tanaproget]]
[[Category: Tanaproget]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 18:05:06 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 12:16:14 2008''

Revision as of 12:16, 28 July 2008

File:1zuc.png

Template:STRUCTURE 1zuc

Progesterone receptor ligand binding domain in complex with the nonsteroidal agonist tanaprogetProgesterone receptor ligand binding domain in complex with the nonsteroidal agonist tanaproget

Template:ABSTRACT PUBMED 15937332

About this StructureAbout this Structure

1ZUC is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget., Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, Appavu C, Li S, Wilhem J, Chopra R, Fensome A, Zhang P, Wrobel J, Unwalla RJ, Lyttle CR, Winneker RC, J Biol Chem. 2005 Aug 5;280(31):28468-75. Epub 2005 Jun 3. PMID:15937332

Page seeded by OCA on Mon Jul 28 12:16:14 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA